120 related articles for article (PubMed ID: 2071896)
21. Invariant chain prevents the HLA-DR-restricted presentation of a cytosolic peptide.
Long EO; LaVaute T; Pinet V; Jaraquemada D
J Immunol; 1994 Aug; 153(4):1487-94. PubMed ID: 8046228
[TBL] [Abstract][Full Text] [Related]
22. Cell surface expression of hybrid murine/human MHC class II beta alpha dimers. Key influence of residues in the amino-terminal portion of the beta 1 domain.
Lechler RI; Sant AJ; Braunstein NS; Sekaly R; Long E; Germain RN
J Immunol; 1990 Jan; 144(1):329-33. PubMed ID: 2404065
[TBL] [Abstract][Full Text] [Related]
23. Immunologically discrete conformation isomers of I-A locus-equivalent class II molecules detected in Lewis rats.
Reske K; Weitzel R
Eur J Immunol; 1985 Dec; 15(12):1229-39. PubMed ID: 3878790
[TBL] [Abstract][Full Text] [Related]
24. Acquisition of peptides by MHC class II polypeptides in the absence of the invariant chain.
Hitzel C; van Endert P; Koch N
J Immunol; 1995 Feb; 154(3):1048-56. PubMed ID: 7822782
[TBL] [Abstract][Full Text] [Related]
25. Analysis of the oligosaccharides on the HLA-DR and DC1 B cell antigens.
Shackelford DA; Strominger JL
J Immunol; 1983 Jan; 130(1):274-82. PubMed ID: 6600184
[TBL] [Abstract][Full Text] [Related]
26. HLA-DR antigens of autologous melanoma and B lymphoblastoid cell lines: differences in glycosylation but not protein structure.
Alexander S; Hubbard SC; Strominger JL
J Immunol; 1984 Jul; 133(1):315-20. PubMed ID: 6609984
[TBL] [Abstract][Full Text] [Related]
27. HLA-DM is present in one-fifth the amount of HLA-DR in the class II peptide-loading compartment where it associates with leupeptin-induced peptide (LIP)-HLA-DR complexes.
Schafer PH; Green JM; Malapati S; Gu L; Pierce SK
J Immunol; 1996 Dec; 157(12):5487-95. PubMed ID: 8955198
[TBL] [Abstract][Full Text] [Related]
28. The alpha 1 domain of the HLA-DR molecule is essential for high-affinity binding of the toxic shock syndrome toxin-1.
Karp DR; Teletski CL; Scholl P; Geha R; Long EO
Nature; 1990 Aug; 346(6283):474-6. PubMed ID: 2377209
[TBL] [Abstract][Full Text] [Related]
29. Two processing pathways for the MHC class II-restricted presentation of exogenous influenza virus antigen.
Pinet V; Malnati MS; Long EO
J Immunol; 1994 May; 152(10):4852-60. PubMed ID: 8176208
[TBL] [Abstract][Full Text] [Related]
30. Peptide binding inhibits protein aggregation of invariant-chain free class II dimers and promotes surface expression of occupied molecules.
Germain RN; Rinker AG
Nature; 1993 Jun; 363(6431):725-8. PubMed ID: 8515815
[TBL] [Abstract][Full Text] [Related]
31. Invariant chain associates with HLA class II antigens via its extracytoplasmic region.
Marks MS; Cresswell P
J Immunol; 1986 Apr; 136(7):2519-25. PubMed ID: 3512715
[TBL] [Abstract][Full Text] [Related]
32. Allele and locus-specific differences in cell surface expression and the association of HLA class I heavy chain with beta 2-microglobulin: differential effects of inhibition of glycosylation on class I subunit association.
Neefjes JJ; Ploegh HL
Eur J Immunol; 1988 May; 18(5):801-10. PubMed ID: 2967765
[TBL] [Abstract][Full Text] [Related]
33. Unassembled HLA-DR beta monomers are degraded rapidly by a nonlysosomal mechanism.
Cotner T
J Immunol; 1992 Apr; 148(7):2163-8. PubMed ID: 1545123
[TBL] [Abstract][Full Text] [Related]
34. Monensin prevents terminal glycosylation of the N- and O-linked oligosaccharides of the HLA-DR-associated invariant chain and inhibits its dissociation from the alpha-beta chain complex.
Machamer CE; Cresswell P
Proc Natl Acad Sci U S A; 1984 Mar; 81(5):1287-91. PubMed ID: 6608726
[TBL] [Abstract][Full Text] [Related]
35. Intracellular and cell surface heterotypic associations of human leukocyte antigen-DR and human invariant chain.
Triantafilou K; Triantafilou M; Wilson KM; Cherry RJ; Fernandez N
Hum Immunol; 1999 Nov; 60(11):1101-12. PubMed ID: 10600008
[TBL] [Abstract][Full Text] [Related]
36. Cell surface expression of class II histocompatibility antigens occurs in the absence of the invariant chain.
Sekaly RP; Tonnelle C; Strubin M; Mach B; Long EO
J Exp Med; 1986 Nov; 164(5):1490-504. PubMed ID: 2430042
[TBL] [Abstract][Full Text] [Related]
37. Anomalous expression of the HLA-DR alpha and beta chains in ovarian and other cancers.
Rangel LB; Agarwal R; Sherman-Baust CA; Mello-Coelho Vd; Pizer ES; Ji H; Taub DD; Morin PJ
Cancer Biol Ther; 2004 Oct; 3(10):1021-7. PubMed ID: 15467430
[TBL] [Abstract][Full Text] [Related]
38. Cathepsin B cleavage and release of invariant chain from MHC class II molecules follow a staged pattern.
Xu M; Capraro GA; Daibata M; Reyes VE; Humphreys RE
Mol Immunol; 1994 Jul; 31(10):723-31. PubMed ID: 8035834
[TBL] [Abstract][Full Text] [Related]
39. HLA-DR associates with specific stress proteins and is retained in the endoplasmic reticulum in invariant chain negative cells.
Schaiff WT; Hruska KA; McCourt DW; Green M; Schwartz BD
J Exp Med; 1992 Sep; 176(3):657-66. PubMed ID: 1512535
[TBL] [Abstract][Full Text] [Related]
40. Structural requirements for pairing of alpha and beta chains in HLA-DR and HLA-DP molecules.
Karp DR; Teletski CL; Jaraquemada D; Maloy WL; Coligan JE; Long EO
J Exp Med; 1990 Mar; 171(3):615-28. PubMed ID: 2307929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
